Cord blood stem cells boost recovery in High-Risk cancer patients
NCT ID NCT03674411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment helps blood cells recover faster, reducing hospital stays and complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?